MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.062
https://www.valueinhealthjournal.com/article/S1098-3015(18)33362-X/fulltext
Title :
MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33362-X&doi=10.1016/j.jval.2018.09.062
First page :
Section Title :
Open access? :
No
Section Order :
64